晚期乳腺癌国际共识指南:第五版定稿
2011年11月3日至5日,欧洲肿瘤学院(ESO)联合欧洲肿瘤内科学会(ESMO)组织全球多学科专家在葡萄牙里斯本召开了第一届晚期乳腺癌国际共识大会,并制定了晚期乳腺癌国际共识指南第一版,随后每两年召开大会并更新指南。2019年11月14日至16日,第五届晚期乳腺癌国际共识大会在葡萄牙里斯本召开,来自全球94个国家的1500位医务人员、患者代表和记者参加了大会,44位全球多学科专家(包括复旦大学附属肿瘤医院胡夕春教授、中国医学科学院肿瘤医院徐兵河教授)对晚期乳腺癌国际共识指南第五版草案进行了讨论和投票表决。随着2019年12月10日至14日第42届美国圣安东尼奥乳腺癌大会、2020年5月29日至31日美国临床肿瘤学会第56届年会相继公布了若干重要的晚期乳腺癌临床研究结果,晚期乳腺癌国际共识指南第五版又进行了补充、修订和更新,并于2020年9月23日发表手稿、2020年11月10日清样定稿。
2020年12月,欧洲肿瘤内科学会《肿瘤学报》将正式发表葡萄牙尚帕利莫基金会临床中心、诺瓦医学院、以色列耶路撒冷希伯来大学、示巴医疗中心、波兰格但斯克医科大学、意大利米兰大学、欧洲癌症研究院、欧洲乳腺癌联盟、欧洲肿瘤学院、普拉托医院、托斯卡纳肿瘤研究所、瑞士热诺利耶医院、日贝瓦大学、法国古斯塔夫鲁西研究所、巴黎索邦大学、奥弗涅克莱蒙大学、让·佩林癌症中心、巴西阿雷格里港肿瘤医院、拉丁美洲肿瘤学协作组、瑞典卡罗林学院、印度加尔各答盐湖城医疗中心、澳大利亚皇家北岸医院、澳大利亚墨尔本大学、悉尼大学、美国北卡罗来纳大学、哈佛大学达纳法伯癌症研究院、转移性乳腺癌网络、旧金山加利福尼亚大学、斯坦福大学、纽约纪念医院斯隆凯特林癌症中心、西班牙马德里肿瘤研究所、巴塞罗那肿瘤研究所、巴塞罗那医院、黎巴嫩贝鲁特美国大学、英国萨塞克斯大学、皇家马斯登医院、加拿大温哥华癌症中心、德国慕尼黑大学、哈雷-维滕贝格马丁路德大学、复旦大学附属肿瘤医院、中国医学科学院肿瘤医院、马来西亚乳腺癌协会、韩国蔚山大学首尔峨山医院、秘鲁国家肿瘤疾病研究所、丹麦奥胡斯大学、日本癌症研究会有明医院联合起草的晚期乳腺癌国际共识指南第五版,全文共计27页,提供了远处转移和局部晚期乳腺癌各个亚型患者诊断、治疗、随访、姑息和支持的最新信息。
据悉,第六届晚期乳腺癌国际共识大会将于2021年11月4日至6日在葡萄牙里斯本召开。
相关链接
Ann Oncol. 2020 Sep 23. Online ahead of print.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP.
Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal; Hadassah University Hospital, Jerusalem, Israel; Sheba Medical Center, Ramat Gan, Israel; Belong.Life, Tel Aviv, Israel; Medical University of Gdansk, Gdansk, Poland; European Institute of Oncology, IRCCS, University of Milan, Milan, Italy; Europa Donna, The European Breast Cancer Coalition, Milan, Italy; European School of Oncology, Milan, Italy; Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy; Clinique de Genolier, Genolier, Switzerland; Riviera-Chablais Hospital, Rennaz, Switzerland; Geneva University Hospital, Geneva, Switzerland; European School of Oncology, Bellinzona, Switzerland; Institut Gustave Roussy, Villejuif, France; University Cancer Institute APHP, Sorbonne University, Paris, France; University Clermont Auvergne, Clermont-Ferrand, France; Centre Jean Perrin, Clermont-Ferrand, France; Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil; Karolinska Institute & University Hospital, Stockholm, Sweden; Salt Lake City Medical Centre, Kolkata, India; The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Sydney Medical School, Sydney, Australia; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA; Dana-Farber Cancer Institute, Boston, USA; Metastatic Breast Cancer Network, Inverness, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; Stanford School of Medicine, Stanford, USA; Memorial Sloan-Kettering Cancer Center, New York, USA; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Clinic of Barcelona, Barcelona, Spain; American University of Beirut Medical Center, Beirut, Lebanon; Brighton & Sussex Medical School, University of Sussex, Brighton, UK; The Royal Marsden Hospital NHS Foundation Trust, London, UK; BC Cancer Agency, Vancouver, Canada; Brustkrebs Deutschland e.V., Munich, Germany; University of Munich (LMU), Munich, Germany; Martin Luther University Halle-Wittenburg, Halle, Germany; Fudan University Shanghai Cancer Center, Shanghai, China; Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea; National Institute of Neoplastic Diseases, Lima, Peru; Aarhus University Hospital, Aarhus, Denmark; Cancer Institute Hospital, Tokyo, Japan.
HIGHLIGHTS
This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients
It provides updates on the management of patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care
Updated diagnostic and treatment algorithms are also provided
All recommendations were compiled by a multidisciplinary group of international experts
Recommendations are based on available clinical evidence and the collective expert opinion of the authors
KEYWORDS: ABC; advanced; breast cancer; ESO-ESMO; guidelines; metastatic
PMID: 32979513
DOI: 10.1016/j.annonc.2020.09.010